Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
The federal government is suing some big pharmacy benefit managers over a system of drug rebates that regulators say has made ...
Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...
Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts and OptumRx — have ...
The Federal Trade Commission (FTC) filed a lawsuit Friday against three major prescription drug benefit managers (PBMs) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback